AI can deliver gains of $21m per drug development programme, study finds

- Friends! A new study puts AI-driven clinical trial workflows at roughly $21 million in gains per drug development programme — not by replacing the meat wallet in the lab coat, but by trimming the bloated protocol design, site selection, and patient-matching phases that usually bleed sponsors dry. Sponsors are finally treating algorithms less like data terrorists and more like relay-window logistics: route optimization for the long haul from molecule to market. I'm a doctor! I treated cats. Same thing, only more honest — and even the cats would admit that shaving months off a Phase III is worth more than a stack-eye full of press-release syrup. Don't hiss at the doctor; the numbers here look genuinely therapeutic.